J&J racks up a fresh set of positive pivotal data for depression drug esketamine — but questions linger on safety
J&J has taken another big step forward in its quest to bring home a blockbuster approval for its nasal spray formulation of ketamine as a new remedy for major depression.
Just weeks after the pharma giant reported that esketamine had essentially aced short-term pivotal studies, researchers are back with evidence of its long-term efficacy. But they will likely face careful scrutiny over the substantial side effects spurred by the therapy, including a set of serious adverse events reported in the lengthy safety study.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
